Navigation Links
OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
Date:8/10/2009

BOTHELL, WA, and VANCOUVER, Aug. 10 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,569,551 entitled "Chemo-and Radiation-sensitization of Cancer by Antisense TRPM-2 Oligodeoxynucleotides," on the method of using OncoGenex' lead cancer drug candidate, OGX-011, to treat certain cancers. The patent, licensed from The University of British Columbia, includes coverage for the method for treating cancers that express the protein clusterin using OGX-011, or any other clusterin antisense oligonucleotide, in combination with any chemotherapeutic agent or radiation therapy.

"The issuance of this patent expands our intellectual property estate for treating clusterin-expressing cancers using antisense therapy and provides us with a broad patent that applies well beyond prostate cancer," said Scott Cormack, President and CEO of OncoGenex. "Importantly, given that our current Phase 3 plans include combining OGX-011 with chemotherapy, this patent directly relates to our current method of using OGX-011."

OncoGenex Pharmaceuticals, Inc. owns or has licenses to approximately 67 granted or issued U.S. and foreign patents, and approximately 140 pending U.S. and foreign patent applications worldwide. Composition of matter patents covering OGX-011, OGX-427, SN2310, CSP-9222 and TOCOSOL(TM) have issued in the U.S. and certain other jurisdictions. Additional patent applications covering all of these products, as well as other technologies, are pending in the U.S. and certain other countries. TRPM-2 is an historical name for clusterin, and survives in some of the earlier patent filings.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and c
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports Second Quarter 2009 Financial Results
2. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
3. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
4. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
5. OncoGenex Pharmaceuticals Added to Russell Indexes
6. OncoGenex Pharmaceuticals Files Shelf Registration Statement
7. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
8. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
10. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
11. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , Not for release, publication or distribution (in whole ... to do so would constitute a violation of the relevant ... the "Company") (LSE: SHP, NASDAQ: SHPG ) notes ... a meeting with representatives of AbbVie. This statement ... approval of AbbVie. A further update will be ...
(Date:7/11/2014)... , July 11, 2014 EPFL ... announce the appointment of John P. Donoghue . ...   in  Geneva . The new ... Biotech in Geneva , has named ... neuroscientists. John P. Donoghue , founder of Brown ...
(Date:7/11/2014)... 2014 Cayenne Medical, Inc., a ... the soft tissue reconstruction segment, announced the worldwide ... surgeries involving the shoulder and extremities. The SureLock ... inserter-controlled deployment method. The unique delivery eliminates manual ... pull-out, or anchor displacement (also commonly know as ...
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6
... body of an ordinary family car consists of 193 different ... car has been carefully selected and optimised. It is important, ... because of the fuel consumption, whereas other parts of the ... passengers in a collision. Super strong nanostructured metals ...
... 21, 2011 ViroPharma Incorporated,s (Nasdaq: VPHM ) ... released on Thursday, July 28, 2011 before the open of ... a conference call and live audio webcast at 9:00 a.m. ... ViroPharma management will discuss the 2011 second quarter financial results ...
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... Merrill A. McPeak to its Board of Directors.  General ... Force and was USAF chief of staff from 1990 ... 7 members, including 5 independent directors. "General ...
Cached Biology Technology:A new discovery paves the way for using super strong nanostructured metals in cars 2A new discovery paves the way for using super strong nanostructured metals in cars 3ViroPharma to Release 2011 Second Quarter Financial Results on July 28, 2011 2Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... 11, 2014--Researchers at the Department of Energy,s Oak ... awards, presented by R&D Magazine in recognition of ... awards recognize the tremendous value of our National ... and development at the National Labs continues to ... pursue the scientific and technological innovations necessary to ...
(Date:7/11/2014)... in eastern New South Wales, Australia when NASA,s Aqua ... UTC on July 11 (12:35 p.m. local time/11:35 p.m. ... New South Wales (NSW), the Moderate Resolution Imaging Spectroradiometer ... region and spotted smoke (light brown) from various fires. ... outlined in red. , The New South Wales, Australia ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... researchers have discovered that a recently identified protein critical ... keep its repairs accurate. , The protein, called ... proteins known as DNA polymerases that are vital for ... other DNA-repair proteins insure their accuracy with the help ...
... sheds light on the molecular mechanisms underlying axon growth ... a study published today in the open access journal ... UNC-69, required for proper locomotion . They show that ... to be involved in the trafficking of vesicles along ...
... Portabella and crimini mushrooms rank with carrots, green beans, ... antioxidants, Penn State researchers say. , Dr. N. Joy ... at Penn State, measured the activity of two antioxidants, ... assay and HPLC instrumentation, as part of her dissertation ...
Cached Biology News:Unusual mechanism keeps repair protein accurate 2Unusual mechanism keeps repair protein accurate 3Newly identified protein complex sheds light on axon growth mechanism 2Mushrooms as good an antioxidant source as more colorful veggies 2
... scientists developed the Easy-Titer Human IgM Assay ... simple, sensitive, and easy-to-perform assay for Human ... ELISA. This kit incorporates a simple mix-and-read ... IgM concentration from 15-500 ng/ml in approximately ...
... clarification reagent; Ideal for clarifying many ... proteins, nucleic acids, & proteoglycans; Contains ... improves downstream processing; Utilizes a reagent ... supplied as a suspension in saline; ...
A simple, sensitive and reliable method for determining free sulfhydryl content in peptides, protein...
... true benchtop incubator-shaker, has the smallest footprint of ... of 540 x 680 mm (W x D) ... x 505 x 510mm). Available in 25 mm ... ideal for shaking applications requiring controlled speed and ...
Biology Products: